Study of dalpiciclib plus HDAC inhibitor in advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two targeted drugs (dalpiciclib and an HDAC inhibitor) for people with HR+/HER2- advanced breast cancer whose disease has progressed after prior CDK4/6 inhibitor treatment. The goal is to see if this new combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have hormone receptor-positive (HR+) and HER2-negative breast cancer that has spread or returned and cannot be removed by surgery.
- You have previously been treated with a CDK4/6 inhibitor (like palbociclib, abemaciclib, or ribociclib) and your cancer grew during or after that treatment.
- You have had no more than one type of chemotherapy for advanced breast cancer.
- You have at least one tumor that can be measured on a scan.
- Your major organs (like bone marrow, liver, kidneys, and heart) are working well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (albumin-bound paclitaxel, dalpiciclib, and an aromatase inhibitor) as a first treatment for women with ER-low, HER2-negative breast cancer that has spread and cannot be removed with surgery. The goal is to see if this combination helps control the cancer.
This trial tests dalpiciclib together with hormone (endocrine) therapy in people with HR-positive, HER2-negative advanced breast cancer whose cancer has already responded poorly to a prior CDK4/6 inhibitor. It aims to see if this combination can better control the cancer after that earlier treatment has failed.
This Phase 2 trial tests dalpiciclib (a cancer medicine) added to standard hormone therapy for women with advanced, hormone-receptor–positive and HER2-negative breast cancer that has serious “visceral crisis” symptoms (like fluid buildup, liver issues, or other urgent organ involvement). It aims to see whether this combination can shrink cancer and improve safety compared with hormone therapy alone.
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
This trial tests a drug called Dalpiciclib for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). It aims to see if it can help stop the cancer from growing.
Hear when a new Advanced HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.